OncoMatch/Clinical Trials/NCT04731844

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

Is NCT04731844 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Curcumin plus Piperine for prostate cancer.

Phase 2RecruitingUniversity of RochesterNCT04731844Data as of May 2026

Treatment: Curcumin plus Piperine — To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Multiple Myeloma

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

University of Rochester · Rochester, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify